17952-1-AP

antibody from Proteintech Group

Targeting: CD274 B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunoprecipitation (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Flow cytometry (Data presented on provider website)

Antibody Data

Product number

17952-1-AP

Provider

Proteintech Group

Proper citation

Proteintech Cat#17952-1-AP, RRID:AB_10597552

Product name

PD-L1/CD274 antibody

Antibody type

Polyclonal

Description

KD/KO validated PD-L1/CD274 antibody (Cat. #17952-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: FC, IF, IHC, IP, WB,ELISA.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice.

Sasaki K, Nishina S, Yamauchi A, Fukuda K, Hara Y, Yamamura M, Egashira K, Hino K
Cellular and molecular gastroenterology and hepatology 2021;11(3):739-762

---

Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response.

Zhao Y, Li S, Lv J, Liu Y, Chen Y, Liu Y, Chen X, Li J, Qin X, Wang X, Shi J, Shi Y, Xiang R
Theranostics 2021;11(15):7425-7438

---

Activity of the growth hormone-releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosis-like granuloma.

Zhang C, Tian R, Dreifus EM, Hashemi Shahraki A, Holt G, Cai R, Griswold A, Bejarano P, Jackson R, V Schally A, Mirsaeidi M
Clinical & translational immunology 2021;10(7):e1310

---

PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1.

Ma Y, Xia P, Wang Z, Xu J, Zhang L, Jiang Y
Neoplasia (New York, N.Y.) 2021 Sep;23(9):912-928

---

Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.

Xu HZ, Li TF, Wang C, Ma Y, Liu Y, Zheng MY, Liu ZJ, Chen JB, Li K, Sun SK, Komatsu N, Xu YH, Zhao L, Chen X
Journal of nanobiotechnology 2021 Sep 6;19(1):268

---

Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in Braf^V600E/Pten^NULL Mice.

Chhabra G, Singh CK, Guzmán-Pérez G, Ndiaye MA, Iczkowski KA, Ahmad N
The Journal of investigative dermatology 2021 Sep 29;

---

TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.

Ren Y, Qian Y, Ai L, Xie Y, Gao Y, Zhuang Z, Chen J, Chen YX, Fang JY
Nature communications 2021 Sep 13;12(1):5405

---

Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma.

Deng Y, Su W, Zhu J, Ji H, Zhou X, Geng J, Zhu J, Zhang Q
Journal for immunotherapy of cancer 2021 Oct;9(10)

---

Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.

Tian W, Sun Y, Cheng Y, Ma X, Du W, Shi W, Guo Q
Thoracic cancer 2021 Oct;12(19):2551-2563

---

Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles.

Yu Q, Tang X, Zhao W, Qiu Y, He J, Wan D, Li J, Wang X, He X, Liu Y, Li M, Zhang Z, He Q
Acta biomaterialia 2021 Oct 1;133:244-256

---

PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.

Wu L, Cai S, Deng Y, Zhang Z, Zhou X, Su Y, Xu D
International immunopharmacology 2021 May;94:107443

---

Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.

Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S, An S, Wu S, Yang C, Chen D, Xu M, Cai M, To KKW, Fu L
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2021 May;8(10):2003404

---

Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.

Al-Badran SS, Grant L, Campo MV, Inthagard J, Pennel K, Quinn J, Konanahalli P, Hayman L, Horgan PG, McMillan DC, Roxburgh CS, Roseweir A, Park JH, Edwards J
The journal of pathology. Clinical research 2021 Mar;7(2):121-134

---

Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs.

Jeon IS, Yoo JD, Gurung S, Kim M, Lee C, Park EJ, Park RW, Lee B, Kim S
Biomaterials 2021 Mar;270:120685

---

WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.

Wu M, Xia X, Hu J, Fowlkes NW, Li S
Nature communications 2021 Jun 9;12(1):3500

---

CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway.

Zheng S, Shen T, Liu Q, Liu T, Tuerxun A, Zhang Q, Yang L, Han X, Lu X
Journal of cellular physiology 2021 Jul;236(7):5373-5386

---

Inhibition of NF-κB is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells.

Lu X, Li Y, Yang W, Tao M, Dai Y, Xu J, Xu Q
Journal of biochemical and molecular toxicology 2021 Jan;35(1):e22621

---

Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity.

Li C, Yao H, Wang H, Fang JY, Xu J
Oncogene 2021 Feb;40(6):1128-1146

---

ZG16 regulates PD-L1 expression and promotes local immunity in colon cancer.

Meng H, Ding Y, Liu E, Li W, Wang L
Translational oncology 2021 Feb;14(2):101003

---

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy.

Li C, Chi H, Deng S, Wang H, Yao H, Wang Y, Chen D, Guo X, Fang JY, He F, Xu J
Journal for immunotherapy of cancer 2021 Aug;9(8)

---

Helicobacter urease suppresses cytotoxic CD8+ T-cell responses through activating Myh9-dependent induction of PD-L1.

Wu J, Zhu X, Guo X, Yang Z, Cai Q, Gu D, Luo W, Yuan C, Xiang Y
International immunology 2021 Aug 23;33(9):491-504

---

KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.

Du W, Zhu J, Zeng Y, Liu T, Zhang Y, Cai T, Fu Y, Zhang W, Zhang R, Liu Z, Huang JA
Cell death and differentiation 2021 Apr;28(4):1284-1300

---

Enhanced response to PD-L1 silencing by modulation of TME via balancing glucose metabolism and robust co-delivery of siRNA/Resveratrol with dual-responsive polyplexes.

Jia L, Gao Y, Zhou T, Zhao XL, Hu HY, Chen DW, Qiao MX
Biomaterials 2021 Apr;271:120711

---

Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells.

Hua S, Gu M, Wang Y, Ban D, Ji H
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021 Apr;23(4):750-756

---

Alpha-Fetoprotein Regulates the Expression of Immune-Related Proteins through the NF-κB (P65) Pathway in Hepatocellular Carcinoma Cells.

Li QT, Qiu MJ, Yang SL, Fang X, He XX, Wang MM, Li YN, Xiong ZF, Huang S
Journal of oncology 2020;2020:9327512

---

Ethyl Acetate Fraction from Hedyotis diffusa plus Scutellaria barbata Exerts Anti-Breast Cancer Effect via miR-200c-PDE7B/PD-L1-AKT/MAPK Axis.

Yang Y, Fang T, Cao YL, Lv YX, Chang QQ, Zhang DD
Evidence-based complementary and alternative medicine : eCAM 2020;2020:3587095

---

PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.

Wang J, Shang S, Li J, Deng H, Ouyang L, Xie H, Zhu H, Li Y, Zuo C
Cancer management and research 2020;12:4999-5008

---

CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.

Song Y, Song W, Li Z, Song W, Wen Y, Li J, Xia Q, Zhang M
Frontiers in oncology 2020;10:488

---

Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.

Cai H, Zhang H, Jiang Y
Frontiers in oncology 2020;10:1079

---

Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.

Takaki H, Hirata Y, Ueshima E, Kodama H, Matsumoto S, Wada R, Suzuki H, Nakasho K, Yamakado K
Journal of vascular and interventional radiology : JVIR 2020 Sep;31(9):1475-1482.e2

---

Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.

Yoon CJ, Chang MS, Kim DH, Kim W, Koo BK, Yun SC, Kim SH, Kim YS, Woo JH
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020 Sep;23(5):780-795

---

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.

Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L
Journal of experimental & clinical cancer research : CR 2020 Sep 7;39(1):180

---

LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.

Liu Z, Li S, Zeng J, Zhou X, Li H, Liu X, Li F, Jiang B, Zhao M, Ma T
Life sciences 2020 Sep 15;257:118068

---

IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models.

Lu SW, Pan HC, Hsu YH, Chang KC, Wu LW, Chen WY, Chang MS
Nature communications 2020 Sep 14;11(1):4611

---

MiR-34a suppresses the proliferation and invasion of gastric cancer by modulating PDL1 in the immune microenvironment.

Yong H, Fu J, Gao G, Shi H, Zheng D, Zhou X
Molecular and cellular probes 2020 Oct;53:101601

---

Adipose Tissue From Type 1 Diabetes Mellitus Patients Can Be Used to Generate Insulin-Producing Cells.

Ikemoto T, Tokuda K, Wada Y, Gao L, Miyazaki K, Yamada S, Saito Y, Imura S, Morine Y, Shimada M
Pancreas 2020 Oct;49(9):1225-1231

---

Epoxyazadiradione exhibit activities in head and neck squamous cell carcinoma by targeting multiple pathways.

Rai V, Aggarwal SK, Verma SS, Awasthee N, Dhasmana A, Aggarwal S, Das SN, Nair MS, Yadav S, Gupta SC
Apoptosis : an international journal on programmed cell death 2020 Oct;25(9-10):763-782

---

Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.

Cai X, Wei B, Li L, Chen X, Liu W, Cui J, Lin Y, Sun Y, Xu Q, Guo W, Gu Y
International immunopharmacology 2020 Nov;88:106858

---

The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway.

Deng R, Zuo C, Li Y, Xue B, Xun Z, Guo Y, Wang X, Xu Y, Tian R, Chen S, Liu Q, Chen J, Wang J, Huang X, Li H, Guo M, Wang X, Yang M, Wu Z, Wang J, Ma J, Hu J, Li G, Tang S, Tu Z, Ji H, Zhu H
Cellular & molecular immunology 2020 Nov;17(11):1163-1179

---

Lactobacillus Attenuate the Progression of Pancreatic Cancer Promoted by Porphyromonas Gingivalis in K-ras^G12D Transgenic Mice.

Chen SM, Hsu LJ, Lee HL, Lin CP, Huang SW, Lai CJ, Lin CW, Chen WT, Chen YJ, Lin YC, Yang CC, Jan MS
Cancers 2020 Nov 26;12(12)

---

BGC823 Cell Line with the Stable Expression of iRFP720 Retains Its Primary Properties with Promising Fluorescence Imaging Ability.

Hu H, Zhang Z, Wang R, Wang Y, Jin J, Cai L, Yang J, Duan H, Wu Z, Fang Z, Liu B
DNA and cell biology 2020 May;39(5):900-908

---

Differentiation of cancer cells upregulates HLA‑G and PD‑L1.

Ullah M, Meziani S, Shah S, Kaci R, Pimpie C, Pocard M, Mirshahi M
Oncology reports 2020 Jun;43(6):1797-1804

---

Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.

Choi E, Chang MS, Byeon SJ, Jin H, Jung KC, Kim H, Lee KL, Kim W, Park JH, Kim KH, Kim JS, Choi IS, Han DS, Ahn HS, Heo SC
Diagnostic pathology 2020 Jun 4;15(1):69

---

PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer.

Lv D, Xing C, Cao L, Zhuo Y, Wu T, Gao N
Oncology letters 2020 Feb;19(2):1223-1234

---

MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.

Cheng M, Duan PG, Gao ZZ, Dai M
Oncology reports 2020 Dec;44(6):2691-2700

---

The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.

Chen TC, Wu CT, Wang CP, Lou PJ, Ko JY, Chang YL
Oral oncology 2020 Dec;111:104945

---

Anti-inflammatory effects of α-MSH through p-CREB expression in sarcoidosis like granuloma model.

Zhang C, Chery S, Lazerson A, Altman NH, Jackson R, Holt G, Campos M, Schally AV, Mirsaeidi M
Scientific reports 2020 Apr 29;10(1):7277

---

Mycobacterium abscessus-Bronchial Epithelial Cells Cross-Talk Through Type I Interferon Signaling.

Zhang C, Asif H, Holt GE, Griswold AJ, Campos M, Bejarano P, Fregien NL, Mirsaeidi M
Frontiers in immunology 2019;10:2888

---

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.

D'Alterio C, Buoncervello M, Ieranò C, Napolitano M, Portella L, Rea G, Barbieri A, Luciano A, Scognamiglio G, Tatangelo F, Anniciello AM, Monaco M, Cavalcanti E, Maiolino P, Romagnoli G, Arra C, Botti G, Gabriele L, Scala S
Journal of experimental & clinical cancer research : CR 2019 Oct 28;38(1):432

---

TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.

Zhang C, Duan Y, Xia M, Dong Y, Chen Y, Zheng L, Chai S, Zhang Q, Wei Z, Liu N, Wang J, Sun C, Tang Z, Cheng X, Wu J, Wang G, Zheng F, Laurence A, Li B, Yang XP
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov 15;25(22):6827-6838

---

Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.

Osborne N, Sundseth R, Gay MD, Cao H, Tucker RD, Nadella S, Wang S, Liu X, Kroemer A, Sutton L, Cato A, Smith JP
American journal of physiology. Gastrointestinal and liver physiology 2019 Nov 1;317(5):G682-G693

---

Bifidobacterium infantis Induces Protective Colonic PD-L1 and Foxp3 Regulatory T Cells in an Acute Murine Experimental Model of Inflammatory Bowel Disease.

Zhou L, Liu D, Xie Y, Yao X, Li Y
Gut and liver 2019 Mar 15;13(4):430-439

---

Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.

Wang T, Chen S, Wang X, Huang Y, Qiu J, Fei Y, Chaulagain A, Chen Y, Wang Y, Lin L, Yan B, Wang Y, Wang W, Zhao W, Zhong Z
Antiviral research 2019 Jun;166:1-10

---

Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.

Wan WJ, Qu CX, Zhou YJ, Zhang L, Chen MT, Liu Y, You BG, Li F, Wang DD, Zhang XN
International journal of pharmaceutics 2019 Jul 20;566:731-744

---

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.

Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H
Molecular cell 2019 Jan 3;73(1):22-35.e6

---

Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.

Chen SW, Li SH, Shi DB, Jiang WM, Song M, Yang AK, Li YD, Bei JX, Chen WK, Zhang Q
The International journal of biological markers 2019 Dec;34(4):398-405

---

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.

Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, Lu H, Fang C, Zhang Y, Liang L, Zhou X, Wang C, Xue Y, Cui Y, Xu J
Nature biomedical engineering 2019 Apr;3(4):306-317

---

PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection.

Yang F, Zeng Z, Li J, Zheng Y, Wei F, Ren X
Frontiers in oncology 2018;8:604

---

Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.

Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N
Oncogene 2018 Sep;37(39):5257-5268

---

A Novel 3D in Vitro Tumor Model Based on Silk Fibroin/Chitosan Scaffolds To Mimic the Tumor Microenvironment.

Li J, Zhou Y, Chen W, Yuan Z, You B, Liu Y, Yang S, Li F, Qu C, Zhang X
ACS applied materials & interfaces 2018 Oct 31;10(43):36641-36651

---

The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.

Takada K, Toyokawa G, Shoji F, Okamoto T, Maehara Y
Clinical lung cancer 2018 Mar;19(2):120-129

---

Effects of three-dimensional collagen scaffolds on the expression profiles and biological functions of glioma cells.

Jia W, Jiang X, Liu W, Wang L, Zhu B, Zhu H, Liu X, Zhong M, Xie D, Huang W, Jia W, Li S, Liu X, Zuo X, Cheng D, Dai J, Ren C
International journal of oncology 2018 Jun;52(6):1787-1800

---

MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling.

Ji X, Wang E, Tian F
Biochemical and biophysical research communications 2018 Jan 1;495(1):1342-1348

---

Bone marrow mesenchymal stromal cells attenuate liver allograft rejection may via upregulation PD-L1 expression through downregulation of miR-17-5p.

Chen Q, Zhou R, Zhang Y, Zhu S, Xiao C, Gong J, Li K, Tang H, Sun C, Zhang J
Transplant immunology 2018 Dec;51:21-29

---

Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.

Wang K, Wang J, Wei F, Zhao N, Yang F, Ren X
Frontiers in immunology 2017;8:456

---

Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.

Kumar S, Davra V, Obr AE, Geng K, Wood TL, De Lorenzo MS, Birge RB
Oncoimmunology 2017;7(1):e1376155

---

Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.

Kikuchi M, Clump DA, Srivastava RM, Sun L, Zeng D, Diaz-Perez JA, Anderson CJ, Edwards WB, Ferris RL
Oncoimmunology 2017;6(7):e1329071

---

A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging.

Buchakjian MR, Merritt NM, Moose DL, Dupuy AJ, Tanas MR, Henry MD
PloS one 2017;12(8):e0183469

---

Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients.

Chen J, Li H, Pang R, Huang J
OncoTargets and therapy 2017;10:2003-2007

---

miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression.

Miao S, Mao X, Zhao S, Song K, Xiang C, Lv Y, Jiang H, Wang L, Li B, Yang X, Yuan Z, Xiu C, Meng H, Sun J
Oncotarget 2017 Sep 22;8(37):62143-62153

---

PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.

Liu S, Chen S, Yuan W, Wang H, Chen K, Li D, Li D
Oncotarget 2017 Nov 21;8(59):99901-99912

---

High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.

Chang YL, Yang CY, Huang YL, Wu CT, Yang PC
Oncotarget 2017 Mar 14;8(11):18021-18030

---

miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.

Jia L, Xi Q, Wang H, Zhang Z, Liu H, Cheng Y, Guo X, Zhang J, Zhang Q, Zhang L, Xue Z, Li Y, Da Y, Zhao P, Zhang R
Biochemical and biophysical research communications 2017 Jun 24;488(2):425-431

---

Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.

Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J
Oncotarget 2017 Jun 20;8(25):41242-41255

---

PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.

Wang J, Xie T, Wang B, William WN Jr, Heymach JV, El-Naggar AK, Myers JN, Caulin C
Cancer prevention research (Philadelphia, Pa.) 2017 Dec;10(12):684-693

---

Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.

Yang CY, Lin MW, Chang YL, Wu CT
Cancer biomarkers : section A of Disease markers 2017 Dec 12;21(1):211-220

---

WITHDRAWN: Prognostic Significance of Programmed Cell Death-Ligand 1 Expression in Patients With Resected Lung Adenocarcinoma.

Hung JJ, Huang SF, Shen YY, Wu YC, Chou TY, Hsu WH
The Annals of thoracic surgery 2016 Oct 13;

---

High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.

Chang YL, Yang CY, Lin MW, Wu CT, Yang PC
European journal of cancer (Oxford, England : 1990) 2016 Jun;60:125-35

---

Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.

Lanzel EA, Paula Gomez Hernandez M, Bates AM, Treinen CN, Starman EE, Fischer CL, Parashar D, Guthmiller JM, Johnson GK, Abbasi T, Vali S, Brogden KA
Cancer immunology, immunotherapy : CII 2016 Dec;65(12):1511-1522

---

Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.

Yang CY, Lin MW, Chang YL, Wu CT, Yang PC
European journal of cancer (Oxford, England : 1990) 2016 Apr;57:91-103

---

Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer.

Jiang L, Zhao Z, Jiang S, Lin Y, Yang H, Xie Z, Lin Y, Long H
Immunologic research 2015 Jul;62(3):316-24

---

Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice.

Kao CJ, Wurz GT, Lin YC, Vang DP, Griffey SM, Wolf M, DeGregorio MW
Cancer immunology research 2015 Jul;3(7):741-50

---

Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma.

Han L, Liu F, Li R, Li Z, Chen X, Zhou Z, Zhang X, Hu T, Zhang Y, Young K, Sun S, Wen J, Zhang M
Oncology letters 2014 Oct;8(4):1461-1469

---

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.

Yang CY, Lin MW, Chang YL, Wu CT, Yang PC
European journal of cancer (Oxford, England : 1990) 2014 May;50(7):1361-9

Western blot

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

mouse heart tissue were subjected to SDS PAGE followed by western blot with 17952-1-AP( PD-L1/CD274 Antibody) at dilution of 1:300

Sample type

tissue

Immunocytochemistry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

The PD-L1/CD274 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human PD-L1/CD274. This antibody recognizes human,mouse,rat antigen. The PD-L1/CD274 antibody has been validated for the following applications: ELISA, IHC, WB, IF analysis.

Appendix

17952-1-AP.pdf

Show more

Immunohistochemistry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human heart using 17952-1-AP(PD-L1 antibody) at dilution of 1:100 (under 10x lens)

Sample type

tissue

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human heart using 17952-1-AP(PD-L1 antibody) at dilution of 1:100 (under 40x lens)

Sample type

tissue